Dr. Yucai Wang is the Founder and Chief Scientist of AlphaNa Bioscience and a Professor at the University of Science and Technology of China (USTC). He received his bachelor’s and Ph.D. degrees from USTC and completed postdoctoral training at Washington University in St. Louis, Georgia Institute of Technology, and the University of Chicago.
Dr. Wang’s research and translational programs focus on programmable RNA medicines, nucleic acid delivery technologies, and in vivo immune engineering. He has led the development and clinical translation of multiple next-generation nucleic acid therapeutics and vaccines, with six programs receiving investigational new drug (IND) clearance from the National Medical Products Administration (NMPA), including programs currently advancing through Phase I and Phase II clinical trials.
His research has also established emerging in vivo immune engineering platforms, including in vivo CAR-T and tolerogenic antigen-presenting cell (Tol-APC) approaches, through preclinical studies and investigator-initiated clinical programs.
Dr. Wang has published more than 100 peer-reviewed articles in leading journals, including Science and Nature Nanotechnology, and his work has received more than 9,000 citations. As Founder and Chief Scientist of AlphaNa Bioscience, he leads a multidisciplinary team dedicated to translating fundamental discoveries in RNA biology and delivery science into next-generation medicines.

Dr. Chao Wang is a Co-Founder of AlphaNa Bioscience and a Professor at the University of Science and Technology of China (USTC). He received his bachelor’s degree from Shanghai Jiao Tong University and his Ph.D. from The Hong Kong University of Science and Technology (HKUST).
Dr. Wang’s research and translational work focus on structural biology, antigen design, and the molecular mechanisms underlying cellular function. As a key scientific and translational leader, he has contributed to the development and clinical advancement of innovative vaccine programs, supporting six investigational new drug approvals from the National Medical Products Administration (NMPA), including candidates in Phase I and Phase II clinical trials.
Dr. Wang has published extensively as a corresponding author in leading journals, including Nature Chemical Biology, Nature Metabolism, and PNAS. He is a recipient of the NSFC Excellent Young Scientist Fund and the Chinese Academy of Sciences Pioneer Hundred Talents Program. At AlphaNa Bioscience, he leads multidisciplinary research teams, translating structural and mechanistic insights into clinically relevant therapeutic strategies.

Zhimin Zhou is Chief Executive Officer and General Manager of AlphaNa Bioscience, where he leads corporate strategy, financing and capital planning, global business development, and day-to-day operations.
He brings more than 20 years of management experience in multinational organizations. His career spans large global corporations and innovative biopharmaceutical companies, with experience in corporate strategy, corporate finance, international partnering, and business operations.
Throughout his career, he has led major cross-border licensing and partnering transactions for innovative therapeutics and multiple substantial equity financing rounds. He has also overseen the expansion of operations across multiple regions and built a global network of strategic partnerships. His broader management experience includes organizational development, oversight of complex businesses, and global supply chain management.